Business Wire

NORGE-MINING

7.2.2023 10:44:10 CET | Business Wire | Press release

Share
ERMA supports Norge Mining in securing finances for responsible sourcing of crucial minerals in Norway to secure EU’s autonomy on Critical Raw Materials

The European Raw Materials Alliance (ERMA) is pleased to announce that it will support Norge Mining’s Norwegian-based sister company Norge Mineraler AS in the exploration and production of vanadium, phosphate and its subsequent derivative phosphorus, and titanium in Norway. All these raw materials are included in the European Union’s 2020 Critical Raw Materials list, highlighting their strategic importance for a resilient European economy.

European production of these materials is critical to lowering the increasing risks associated with imported supply, as well as supporting Europe to achieve its 2050 net zero carbon emissions target. Currently, China produces approximately 59% of the world’s vanadium and 41% of titanium, while 34% of traded phosphate rock is sourced from Morocco, according to the latest EU figures. Before Russia’s invasion of Ukraine, Russia was the world’s largest supplier of aerospace-grade titanium.

Norge Mineraler AS holds 61 exploration licences, totalling more than 520 square kilometres in the Bjerkreim-Sokndal basin, located in southwestern Norway. The area’s large deposits of high-grade raw materials, and the company’s core focus on sustainable and responsible mining, make the project fully aligned with ERMA’s vision, as it will contributes to ensuring reliable, secure, and sustainable access to raw materials as key enablers for a globally competitive, green, and digital Europe.

Bernd Schäfer, CEO and Managing Director of EIT RawMaterials, which manages ERMA, commented: “Europe is in an excellent position: we can use our advantage in clean tech innovation and skills development to turn the industry into a powerhouse of innovation and change and, in doing so, achieve the highest social and environmental standards for European mining, just as Norge Mineraler AS is doing.”

“Raw materials have a huge impact on our energy and economic security and are critical to securing our strategic autonomy. The current geopolitical crisis and global supply chain disruptions are a reminder that we need our own production, and this is of huge urgency for leaders across the Continent.

In the coming decades, the transition to green energy will significantly increase the global demand for vanadium, a material that not only is in high demand by the steel industry but also has great potential for sustaining clean technologies. Vanadium batteries provide efficient power storage for renewable energy, such as hydro, wind, and solar. By 2050, there will be a 173% increase in the production of vanadium used in technologies essential to a low-carbon future, according to the World Bank Group report, ‘The Mineral Intensity of the Clean Energy Transition’.

Titanium, a strong, lightweight, and extremely resilient raw material, is widely deployed in aerospace, aviation, and automotive manufacturing. Phosphate is not only a key ingredient in fertilisers, which makes it critical to food security of the planet but is also increasingly used in LFP (lithium iron phosphate) batteries for electric vehicles and in the production of white phosphorous, another EU Critical Raw Material.

John Vergopoulos, Chairman of Norge Mineraler AS, commented: “Raw materials are finally getting the attention they deserve, and we are determined to help Europe secure a domestic supply of responsibly sourced critical raw materials to enable its successful transition to renewable energy sources. With the environment and community at the top of our corporate agenda, we are proud that Norge Mineraler AS is striving to meet the highest Environmental, Social, and Governance (ESG) standards for mining vanadium, phosphate, and titanium in Europe.”

Michael Wurmser, founder of Norge Mining Ltd, commented: "Today we celebrate an important milestone for Europe's long-term access to key raw materials for the energy transition and food security. The support of the EU and its organisations ERMA and EIT RawMaterials will enable Norge Mining to implement the relevant projects, which can cost at least €2 billion. This makes cooperation between public and private institutions in the development of sustainable mining infrastructure in Europe all the more important."

ENDS

Note for editors

Norway has significant, untapped mineral resources, and the country generates almost 100% of its energy from sustainable sources, reducing the carbon footprint of mining operations to a minimum. Exploration drilling and analytics at Norge Mineraler AS’s Storeknuten deposit put the estimated mineral resource at almost 1 billion tonnes which represents only about 1.4% of the total volume of at least 70 billion tonnes of Norge Mining’s phosphate rock. While the company will focus on the 410 million tonnes of high-grade minerals, the vast reserves underline the potential for Europe to have a steady and sustainably mined CRM supply for decades to come. The mine is set to begin operation in 2027.

The company uses innovation and technology to minimise environmental impact. It is also in collaboration and constant communication with the local community through its Community Liaison Officer, providing a clear and consistent approach to maintain its Social License to Operate.

About the European Raw Materials Alliance (ERMA)

Metals, minerals, and advanced materials are the key enablers for a globally competitive, green, and digital Europe. The European Raw Materials Alliance (ERMA) contributes to ensuring reliable, secure, and sustainable access to raw materials. ERMA’s vision is to secure access to critical and strategic raw materials, advanced materials, and processing know-how for EU Industrial Ecosystems. The alliance brings together all relevant stakeholders, including industrial actors along the value chain, Member States and regions, trade unions, civil society, research and technology organisations, investors, and NGOs. ERMA is managed by EIT RawMaterials, a Knowledge and Innovation Community of the European Institute of Innovation and Technology (EIT), a body of the European Union.
erma.eu

About Norge Mining Ltd.

Norge Mining Ltd is an Anglo-Norwegian natural resources company focused on mineral exploration in Norway. The Company’s Mineral Resource Estimates from the Bjerkreim-Sokndal Exploration Project have confirmed world-class deposits of the EU Critical Raw Materials phosphate and vanadium along with large quantities of titanium.

Norge Mining holds 61 exploration licences, totalling more than 520 square kilometres, in southwest Norway through its 100%-owned Norwegian subsidiary, Norge Mineraler AS. The Company’s programme of exploration work, building on earlier studies by the Geological Survey of Norway (NGU), is now in the prefeasibility study stage.

Founded in November 2018, the Company is headquartered in the UK and its ambition is to become a substantial, sustainable, and strategically important exploration and mining business focused on Critical Raw Materials in Europe.

For further information, please visit www.norgemining.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230206005592/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye